Guess which ASX share is booming on 1600% revenue growth

iCandy's revenue skyrocketed in the first half of FY22, but is the result as sweet as it looks?

| More on:
two young men sit side by side with gaming controllers pumping their fists and celebrating with joyous looks on their faces at their achievements in the video game they are playing.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ICandy records a 1600% uplift in revenue along with record EBITDA
  • The company's strong performance is mainly due to the acquisition of Lemon Sky Studios
  • Management is confident about iCandy's future outlook with a strong pipeline of work over the next three years

The iCandy Interactive Ltd (ASX: ICI) share price is flying 19.74% higher today to 9.1 cents after the company posted its results for the first half of FY22.

The ASX-listed freemium mobile games developer's shares are currently trading for 9.1 cents each after closing on Wednesday at 7.6 cents.

Let's check if the iCandy result is as sweet as it sounds.

What did iCandy report in 1H FY22?

Here is a snapshot of the key highlights for 1H FY22, which are sending the iCandy share price through the roof today.

The astronomical jump in revenue was due to iCandy's new subsidiary, Lemon Sky Studios. This game and animation studio is known for developing games such as Call of Duty Infinite Warfare, Need for Speed Hot Pursuit, Spider-Man and Marvel's Avengers.

Lemon Sky Studios has assisted iCandy with developing three non-fungible token (NFT) Generative Art projects, as well as nine NFT/Metaverse gaming projects.

ICandy paid $44.5 million comprised of cash and shares for this acquisition.

Prior to this, iCandy also acquired 51% of Storms, a Southeast Asian-based game developer.

ICandy's ultimate goal is to become the leading integrated metaverse gaming platform globally.

Due to the acquisitions, iCandy's employee expenditures lifted from $0.3 million in 1H FY21 to $3.05 million in 1H FY22. This was the biggest uptick in operational expenses.

Operating cash flow went up from negative $1.06 million in 1H FY21 to $3.86 million in 1H FY22. However, iCandy spent $21.3 million in cash on acquisitions for 1H FY22.

What else happened in 1H FY22?

In March, iCandy announced its NFT project with Froyo Games and is expected to be finished in the last quarter of FY22.

ICandy is still developing its signature metaverse game Metal Genesis and hopes a playable demo will be ready by the last quarter of FY22.

Metal Genesis is an armoured robo-suit war machine-themed and player-vs-player metaverse virtual world game being developed by Lemon Sky Studios.

Management confident about outlook

ICandy management advised it has a pipeline of three years for work. Management plans to lift the company headcount by 20% by the end of the year.

Outside of game development, iCandy is seeing demand for animation development services from global streaming and content providers.

Management said it expects the recent revenue trend to continue.

iCandy share price snapshot

In the last year, the iCandy share price has risen by 53% but has dropped 8% in the past month. In contrast, the S&P/ASX 200 Index (ASX: XJO) is down 9% in the last year and 2% in the last month.

The market capitalisation of iCandy is around $113 million.

Motley Fool contributor Raymond Jang has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

A group of business people in a board room hear the latest company report
Earnings Results

Key takeouts for ASX shares this earnings season: CBA analysis

Profits were weaker but plenty of dividends were splashed about this earnings season.

Read more »

Hand of a woman carrying a bag of money, representing the concept of saving money or earning dividends.
Earnings Results

Which ASX shares delivered the biggest profit jumps of the earnings season?

These companies revealed at least a 70% profit boost in their latest earnings reports.

Read more »

A man and woman sit next to each other looking at each other and feeling excited and surprised after reading good news about their shares on a laptop.
Earnings Results

Why this ASX 300 share is leaping 14% despite being branded a 'sell'

Falling profits are putting investors off the fund manager.

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Technology Shares

Life360 share price rockets 24% after smashing FY23 earnings expectations

This tech stock delivered a very strong result this morning. How strong was it?

Read more »

a man in a shirt and tie holds his chin in thoughtful contemplation and looks skywards as if thinking about something while a graphic of a road with many ups and downs unfurls behind him.
Earnings Results

What's with the Neuren Pharmaceuticals share price today?

The full market reaction to the Daybue developer's FY23 earnings report won't be seen until tomorrow.

Read more »

Two workers at an oil rig discuss operations.
Earnings Results

2 ASX energy shares going gangbusters on today's earnings results

The ASX energy shares are drawing investor interest today after releasing their half-year earnings results.

Read more »

Man pointing at a blue rising share price graph.
Earnings Results

This ASX 300 stock just jumped 12%! Here's why

The ASX 300 stock is impressing investors with its half-year earnings results.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Earnings Results

Mesoblast share price tumbles on US$32.5m half-year loss

This biotech continues to burn cash.

Read more »